Plus Therapeutics, Inc. (PSTV) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Austin, TX, アメリカ. 現CEOは Marc H. Hedrick.
PSTV を有する IPO日 2001-07-11, 21 名の正社員, に上場 NASDAQ Capital Marke, 時価総額 $13.67M.
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
